Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 130K | 56K | 3M | 500K | 3M |
| Gross Profit | 45K | -138K | 3M | 500K | -334K |
| Operating Income | -24M | -17M | -3M | -2M | -2M |
| EBITDA | -24M | -10M | 6M | -3M | -1M |
| Net Income | -19M | -11M | 5M | -3M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.10
+6.06% today
1Y Change
-65.26%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Serina Therapeutics, Inc. (SER) is a Healthcare stock with a market cap of $20.00M and listed on AMEX. The stock last traded around $2.10 and down 65.3% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +132.1%, EPS growth of -26.5%, a dividend yield of 0.0%. What stands out right now is revenue +132.1%, EPS -26.5%, free cash flow -4.6% with operating margin -18478.5% and ROIC -709.0%. Valuation already assumes a fairly strong business story at price/sales 139.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SER price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SER
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SER Max Drawdown
-79.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SER and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.5M
+593.0% YoY
FY Net Income
-$1.3M
+52.8% YoY
Free Cash Flow
-$2.4M
-13.1% YoY
Revenue Growth
+132.1%
EPS Growth
-26.5%
Gross Margin
43.8%
Net Margin
-14755.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 130K | 56K | 3M | 500K | 3M |
| Gross Profit | 45K | -138K | 3M | 500K | -334K |
| Operating Income | -24M | -17M | -3M | -2M | -2M |
| EBITDA | -24M | -10M | 6M | -3M | -1M |
| Net Income | -19M | -11M | 5M | -3M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 4M | 8M | 645K | 584K |
| Total Assets | 7M | 7M | 9M | 3M | 3M |
| Total Liabilities | 7M | 6M | 41M | 21M | 15M |
| Shareholder Equity | -37K | 641K | 4M | -17M | -12M |
| Total Debt | 196K | 268K | 3M | 18M | 13M |
| Net Debt | -3M | -3M | -4M | 17M | 13M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-8.4% YoY
Capital Expenditures
108K
-1020.0% YoY
Free Cash Flow
2M
-13.1% YoY
Key ratios
Gross Margin
43.8%
Operating Margin
-18478.5%
Net Margin
-14755.4%
ROE
-1468.2%
Debt / Equity
-84.92x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.